Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu), a human FcRn-blocking ...

MuSK antibody positive adults and pediatric gMG patients aged 12 and older. FDA Approves New Treatment for Generalized ...

The US Food and Drug Administration (FDA) has approved nipocalimab (Imaavy) injection for the treatment of adults and ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior ...